CoChat

Old and new acetylcholinesterase inhibitors for Alzheimer’s disease

Galimberti, Daniela, Scarpini, Elio · 2016 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD. AChEIs reversibly inhibit acetylcholinesterase (AChE), thus increasing the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission. These drugs provide symptomatic short-term benefits, without clearly counteracting the progression of the disease. AREAS COVERED: On the wake of successful clinical trials which lead to the marketing of AChEIs donepezil, rivastigmine and galantamine, many compounds with AChEI properties have been developed and tested mainly in Phase I-II clinical trials in the last twenty years. Here, we review clinical trials initiated and interrupted, and those ongoing so far. EXPERT OPINION: Despite many clinical trials with novel AChEIs have been carried out after the registration of those currently used to treat mild to moderate AD, none so far has been successful in a Phase III trial and marketed. Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters. Moreover, such treatments should be started in very mild phases of the disease, and preventive strategies addressed in elderly people.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2016.1216972

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Birks J, 2006, Cochrane Database Syst Rev, 1, CD005593
  2. Abd Razik BM, 2016, Med Chem, 12

Cited by

See all 126

Metadata

Authors
Galimberti, D., & Scarpini, E.
Affiliations
University of Milan (IT)
Corresponding author
Galimberti, Daniela
Venue
Expert Opinion on Investigational Drugs
Published
2016-08-05
Volume
25
Issue
10
Pages
1181-1187
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2487848811
Cited by
117
References
27
Citations by year
2026: 8 · 2025: 14 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 14 · 2019: 11 · 2018: 11 · 2017: 14 · 2016: 1
FWCI
10.52
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
acetylcholinesterase inhibitors, Alzheimer's disease, donepezil, rivastigmine, galantamine, memantine, cholinergic neurotransmission, acetylcholine, clinical trials, drug development, early treatment, multifactorial therapy
MeSH terms
Acetylcholine, Aged, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Humans, Severity of Illness Index, Drug Design, Treatment Outcome, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/13543784.2016.1216972
The paper
Galimberti, D., & Scarpini, E. (2016). Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1216972

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.